Spiro Rombotis, President and Chief Executive Officer, Cyclacel Pharmaceuticals dives into the insights about cell cycle check point control that have led to the development of fadraciclib, a potent orally and intravenously available inhibitor of CDK2 and CDK9 cancer pathways. Drawing on the vision of the company's founding scientist, Professor Sir David Lane, the mission of Cyclacel is to provide cancer patients with a treatment that allows them to live with their cancer and not die from it.
#Cyclacel #fadra #cancer #solidtumors
Cyclacel.com
Download the transcript here
Empowered Patient Podcast